How We Provide Onsite Monitoring Support Across Europe

Lessons Learned from More Than 100 Clinical Trials

By Patricio Ledesma, Founder and CEO, Sofpromed

After more than 15 years managing clinical trials across Europe, I have learned that one of the biggest challenges in multinational studies is ensuring consistent, high-quality onsite monitoring across multiple countries.

Sponsors often start with an excellent protocol, a solid database, and strong sites, but the success of a trial can still depend heavily on the quality and consistency of its Clinical Research Associates (CRAs).

At Sofpromed, we have provided onsite monitoring support in more than 100 clinical trials across Europe.

During that time, we have helped pharmaceutical companies, biotechnology sponsors, medical device manufacturers, and academic research organizations access experienced CRAs under a centralized European model.

In this article, I will explain how our onsite monitoring solution works, why many sponsors struggle with multi-country monitoring, and why an increasing number of companies choose Sofpromed as a single vendor to manage CRA activities throughout Europe.

The Growing Complexity of Multinational Clinical Trials

Clinical trials continue to become more global every year.

Sponsors frequently conduct studies involving:

• Spain
• Germany
• France
• Italy
• Poland
• Netherlands
• Belgium
• Czech Republic
• Austria
• Portugal

and many other European countries.

While expanding geographically can accelerate recruitment, it also creates substantial operational challenges.

Some of the most common issues include:

• Multiple local monitoring vendors
• Different CRA quality standards
• Inconsistent reporting practices
• Variable monitoring visit frequencies
• Communication barriers
• Delays in issue escalation
• Lack of oversight across countries
• Budget overruns

I have seen sponsors manage ten countries using more than 5 different monitoring providers.

Although each provider may perform adequately within its own territory, the sponsor often ends up spending significant time coordinating activities across the entire study.

This fragmented model can create considerable administrative burden.

For this reason, many sponsors prefer working with a single partner capable of coordinating CRA activities across multiple European countries.

Why Onsite Monitoring Remains Critical

Despite advances in remote monitoring and risk-based monitoring, onsite monitoring continues to play a critical role in clinical trial quality.

Experienced CRAs perform important activities such as:

Source Data Verification

CRAs verify that:

• Data entered into the eCRF matches source documents.
• Protocol requirements are followed.
• Patient eligibility requirements are met.
• Safety information is accurately recorded.

Investigational Product Oversight

Monitoring visits help ensure:

• Drug accountability records are complete.
• Storage conditions remain compliant.
• Dispensing logs are accurate.
• Temperature excursions are identified and addressed.

Protocol Compliance Assessment

A skilled CRA can identify:

• Protocol deviations
• Missing assessments
• Visit window issues
• Safety reporting concerns
• Documentation gaps

before they become significant inspection findings.

Site Support

One often overlooked benefit of onsite monitoring is relationship building.

The best CRAs do far more than review data.

They help:

• Investigators
• Study coordinators
• Pharmacists
• Site staff

solve problems efficiently and maintain study momentum.

The Challenge of Multi-Country CRA Management

Managing monitoring activities across Europe can be surprisingly difficult.

Consider a sponsor running a Phase III oncology trial in:

• Germany
• France
• Italy
• Spain
• Poland
• Netherlands
• Belgium

Each country may have:

• Different languages
• Different site expectations
• Different monitoring practices
• Different vendor contracts

Without centralized oversight, sponsors frequently encounter:

Inconsistent Monitoring Reports

One CRA may provide highly detailed reports.

Another may submit minimal documentation.

The result is inconsistent quality.

Variable Escalation Standards

A major protocol deviation might be escalated immediately in one country but remain unresolved for weeks in another.

Multiple Vendor Management Efforts

Sponsors may need to:

• Review several contracts
• Process multiple invoices
• Attend numerous vendor meetings
• Manage separate performance metrics

This increases operational complexity significantly.

Sofpromed's Solution: One Vendor, Europe-Wide Monitoring Support

At Sofpromed, we have developed a centralized model designed specifically to address these challenges.

Our objective is simple:

Provide high-quality local CRAs while maintaining centralized oversight and accountability.

Sponsors work with a single vendor.

We manage the CRA network.

We coordinate performance.

We ensure quality standards remain consistent.

We provide a unified communication approach across all participating countries.

This significantly simplifies sponsor oversight.

Senior CRA Profiles

One of the differentiators our clients appreciate most is our focus on senior CRA resources.

Clinical trials are becoming increasingly complex.

Many studies involve:

• Oncology
• Rare diseases
• Cell and gene therapies
• Advanced therapies
• Medical devices
• Complex adaptive designs

These studies require experienced professionals.

At Sofpromed, we prioritize senior-level CRA profiles with substantial monitoring experience.

Many of our CRAs have:

• Extensive oncology experience
• Phase I through Phase IV expertise
• Inspection readiness experience
• Risk-based monitoring experience
• Strong site relationship management skills

The value of a senior CRA becomes evident when unexpected challenges arise.

Experienced monitors can often identify potential issues weeks or months before they become major problems.

This proactive approach saves sponsors time and money.

Countries Where We Can Provide CRA Support

Sofpromed can support monitoring activities across numerous European countries.

Below are the ten largest countries in the European Union by population, all of which can be covered through our CRA network.

Table 1: EU countries in which Sofpromed provides onsite monitoring support

In addition, we can often support projects in:

• Portugal
• Austria
• Hungary
• Slovakia
• Croatia
• Slovenia
• Bulgaria
• Ireland
• Denmark
• Sweden
• Finland
• Baltic countries

and other European territories depending on project requirements.

Advantages of Using a Single Vendor Across Europe

1. Simplified Vendor Management

Rather than managing numerous local providers, sponsors interact with a single project management structure.

Benefits include:

• One contract
• One point of contact
• One governance process
• Centralized invoicing

This reduces administrative burden considerably.

2. Consistent CRA Quality

We apply standardized processes across countries to promote consistent performance.

This helps ensure:

• Similar monitoring standards
• Comparable report quality
• Consistent escalation pathways
• Harmonized communication

3. Faster Study Start-Up

When sponsors need rapid study deployment, engaging multiple local monitoring vendors can delay progress.

A centralized model allows faster mobilization of resources.

This becomes particularly valuable in competitive recruitment studies.

4. Better Budget Control

Sponsors frequently report that one of the greatest benefits of our model is improved budget predictability.

Instead of tracking multiple local contracts with varying fee structures, they can operate under a unified commercial framework.

This improves forecasting and financial oversight.

5. Centralized Oversight

Our project management teams maintain visibility across all participating countries.

This allows earlier identification of:

• Recruitment risks
• Monitoring backlog
• Site performance concerns
• Protocol compliance issues

before they affect study milestones.

Supporting Different Therapeutic Areas

Over the years, our CRA teams have supported studies across numerous therapeutic areas.

Examples include:

Oncology

This remains one of our strongest areas of experience.

Our teams have monitored studies involving:

• Solid tumors
• Hematological malignancies
• Immunotherapy
• Targeted therapies
• Rare cancers

Neurology

We have supported trials involving:

• Alzheimer's disease
• Parkinson's disease
• Multiple sclerosis
• Epilepsy

Psychiatry

Experience includes studies involving:

• Major depressive disorder
• Bipolar disorder
• Schizophrenia
• Anxiety disorders

Rare Diseases

Rare disease studies often require particularly experienced CRAs because of:

• Small patient populations
• Complex protocols
• Intensive monitoring requirements

Senior monitoring support can be especially valuable in these programs.

Flexible Resourcing Models

Sponsors increasingly seek flexibility.

For this reason, Sofpromed can support different engagement models.

Full-Service Monitoring

We provide:

• Site selection support
• Site initiation visits
• Routine monitoring visits
• Close-out visits

under a complete monitoring package.

Functional Service Provider (FSP) Model

Many sponsors choose an FSP approach.

Under this model, dedicated CRA resources become an extension of the sponsor's team.

Benefits include:

• Predictable costs
• Flexible scalability
• Long-term continuity

Rescue Projects

Occasionally sponsors encounter operational challenges during an ongoing trial.

Examples include:

• Underperforming sites
• Monitoring backlog
• Resource shortages
• Vendor transitions

We can rapidly deploy experienced CRA resources to help stabilize study operations.

Why Clients Value Our Centralized Control Model

One of the most common pieces of feedback we receive from clients concerns centralized oversight.

Sponsors appreciate knowing that:

• All CRAs are coordinated centrally.
• Performance metrics are reviewed regularly.
• Escalations are monitored consistently.
• Communication channels remain clear.

Instead of receiving fragmented information from multiple vendors, sponsors receive a consolidated view of study progress.

This creates greater transparency and accountability.

For global sponsors headquartered in the United States, Canada, or Asia-Pacific regions, this model can significantly simplify European operations.

Lessons Learned from More Than 100 Clinical Trials

After supporting more than 100 clinical trials with monitoring services across Europe, I have observed several recurring success factors.

Invest in Experienced CRAs

The least expensive option is not always the most cost-effective.

Senior CRAs often deliver greater efficiency, better issue identification, and improved site relationships.

Standardize Monitoring Expectations

Consistency across countries matters.

Uniform monitoring standards reduce variability and improve study quality.

Establish Clear Escalation Pathways

Issues should be escalated rapidly and consistently.

Waiting weeks to address critical findings can create substantial downstream risks.

Focus on Communication

Regular communication between:

• Sponsor
• Project management
• CRAs
• Sites

remains one of the strongest predictors of study success.

Maintain Centralized Oversight

Sponsors benefit from visibility across the entire study rather than managing each country independently.

A centralized monitoring model frequently leads to improved operational efficiency.

Final Words

In my experience, multinational onsite monitoring is one of the most operationally demanding aspects of running a clinical trial in Europe.

Recruiting the right CRA in one country can be challenging.

Coordinating experienced CRAs across multiple countries simultaneously is even more difficult.

At Sofpromed, we have built our monitoring support model specifically to address these challenges.

Through our network of experienced senior CRAs, centralized project oversight, and flexible service delivery approach, we help sponsors conduct studies throughout Europe while working through a single vendor relationship.

Whether a sponsor requires monitoring support in Germany, France, Italy, Spain, Poland, the Netherlands, Belgium, Romania, the Czech Republic, Greece, or multiple countries simultaneously, our goal remains the same: to provide high-quality onsite monitoring services, experienced CRA professionals, consistent oversight, and cost-effective execution.

After supporting more than 100 clinical trials across Europe, I remain convinced that successful monitoring is not simply about conducting site visits.

It is about building strong relationships with sites, identifying risks early, maintaining consistent quality standards, and providing sponsors with the confidence that their studies are being monitored effectively across every participating country.

That is precisely the approach we strive to deliver at Sofpromed every day.